Table 2.
Univariate and multivariate analysis of baseline predictors of overall survival.
| Features | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95%CI) | p Value 1 | HR (95%CI) | p Value 1 | |
| Sex (F vs. M) | 0.96 (0.72–1.28) | 0.764 | ||
| Age at HCC enrollment | 1.29 (0.87–1.92) | 0.038 | 1.02 (1.00–1.04) | 0.120 |
| Etiology (viral vs. others) | 1.19 (0.85–1.69) | 0.314 | ||
| Diameter (≥5 cm vs. <5 cm) | 1.79 (1.26–2.55) | 0.001 | 1.50 (1.03–2.18) | 0.034 |
| Child-Pugh score (B–C vs. A) | 1.63 (1.17–2.27) | 0.004 | 1.41 (0.99–2.01) | 0.042 |
| BCLC stage (A vs. 0) | 2.07 (1.46–2.95) | <0.001 | 1.79 (1.22–2.62) | 0.003 |
| HCC Grade (3 vs. 1–2) | 1.43 (0.98–2.09) | 0.061 | ||
| PVT (yes vs. no) | 1.84 (1.29–2.63) | 0.001 | 1.03 (0.56–1.89) | 0.918 |
| Malignant PVT (yes vs. no) | 2.20 (1.51–3.21) | <0.001 | 2.34 (1.24–4.44) | 0.009 |
| Type of treatment (locoregional vs. surgical) | 1.29 (0.84–2.00) | 0.247 | ||
| AFP ≥ 20 ng/mL (vs. < 20 ng/mL) | 1.17 (0.88–1.55) | 0.285 | ||
| AFP ≥ 200 ng/mL (vs. < 200 ng/mL) | 1.27 (0.82–1.99) | 0.287 | ||
| AFP ≥ 400 ng/mL (vs. < 400 ng/mL) | 1.11 (0.67–1.83) | 0.688 | ||
| AFP ≥ 1000 ng/mL (vs. < 1000 ng/mL) | 2.29 (1.35–3.89) | 0.002 | 2.20 (1.28–3.78) | 0.004 |
1 Cox regression analysis; CI: confidence interval; AFP: alpha-fetoprotein; BCLC: Barcellona Clinic Liver Cancer; HCC: hepatocellular carcinoma; HR: hazard ratio; PVT: portal vein thrombosis.